Researchers develop ultasensitive blood test to predict recurrence of gastric cancers

Researchers develop ultasensitive blood test to predict recurrence of gastric cancers
Credit: AI-generated image (disclaimer)

Researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore, working with colleagues in the Netherlands, developed a blood test that can predict recurrence of gastric cancer in patients after surgery. A description of their test, which is still experimental, was published online Jan. 27 in the journal Nature Communications.

Investigators analyzed from 50 patients with who participated in the CRITICS trial, a phase III, randomized controlled study of chemotherapy given at about the time of surgery. They performed deep sequencing of both circulating cell-free DNA (cfDNA) and of to look for mutations. Subtracting the white blood cells' information from cfDNA yielded data investigators could use to predict cancer recurrence within nine weeks following preoperative treatment and surgery.

"We performed this study to see if we could predict whether gastric cancers would recur using noninvasive liquid biopsies. Using a deep sequencing approach of cell-free DNA and white blood cells, we found an outstanding prediction of whether the therapy was successful," says senior study author Victor Velculescu, M.D., Ph.D., professor of oncology, pathology and medicine. Velculescu also is co-director of the Kimmel Cancer Center's cancer genetics and epigenetics program, and associate director for precision medicine.

Alessandro Leal, M.D., Ph.D., lead author of the paper on the study and former graduate student at the Johns Hopkins University School of Medicine says, "Patients who did not have mutations in the blood after surgery were all cured of , while patients who had mutations in the blood typically recurred. We were able to predict patient outcome about nine months earlier through the than we otherwise could have through clinical evaluation."

More information: Alessandro Leal et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer, Nature Communications (2020). DOI: 10.1038/s41467-020-14310-3

Journal information: Nature Communications
Citation: Researchers develop ultasensitive blood test to predict recurrence of gastric cancers (2020, January 28) retrieved 23 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New blood test uses DNA 'packaging' patterns to detect multiple cancer types


Feedback to editors